Paul Tudor Jones Axsome Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $376,919 - $583,028	6,453 Added 27.04%	30,321 $2.18 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $1.39 Million - $1.79 Million	23,868 New	23,868 $1.47 Million
Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $839,548 - $1.63 Million	-23,282 Reduced 53.08%	20,580 $918,000
Q2 2022 Aug 15, 2022	SELL	$21.74 - $46.75 $741,442 - $1.59 Million	-34,105 Reduced 43.74%	43,862 $1.68 Million
Q1 2022 May 16, 2022	BUY	$23.7 - $41.39 $798,524 - $1.39 Million	33,693 Added 76.1%	77,967 $3.23 Million

Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $1.41 Million - $2 Million	-46,055 Reduced 50.99%	44,274 $1.67 Million
Q3 2021 Nov 15, 2021	BUY	$19.91 - $68.26 $1.27 Million - $4.35 Million	63,668 Added 238.81%	90,329 $2.98 Million
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $843,850 - $1.23 Million	-16,667 Reduced 38.47%	26,661 $1.8 Million
Q1 2021 May 17, 2021	BUY	$55.91 - $81.44 $2.18 Million - $3.17 Million	38,925 Added 884.06%	43,328 $2.45 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $595,331 - $776,776	-8,978 Reduced 67.1%	4,403 $359,000
Q3 2020 Nov 16, 2020	BUY	$68.34 - $85.84 $478,516 - $601,051	7,002 Added 109.77%	13,381 $953,000
Q2 2020 Aug 14, 2020	BUY	$49.87 - $98.69 $318,120 - $629,543	6,379 New	6,379 $525,000
Q1 2020 May 15, 2020	SELL	$41.2 - $101.31 $967,087 - $2.38 Million	-23,473 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $392,233 - $2.49 Million	23,473 New	23,473 $2.43 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.